A phase II study of oral infigratinib in adult patients with advanced or metastatic solid tumors with FGFR1-3 gene fusions or other FGFR genetic alterations
Completed
This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in…
Phase: PHASE2 • Sponsor: Sameek Roychowdhury
Last updated Mar 03, 2026 14:07 UTC